Enterprise Value
-15.11M
Cash
22.46M
Avg Qtr Burn
-18.8M
Short % of Float
2.15%
Insider Ownership
21.92%
Institutional Own.
44.51%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
AMT-101 (IL-10 oral agonist) Details Pouchitis, Rheumatoid arthritis, Ulcerative colitis | Phase 3 Initiation | |
AMT-101 (IL-10 oral agonist) +anti-TNFα Details Rheumatoid arthritis | Failed Discontinued | |
AMT-101 (IL-10 oral agonist) Details Ulcerative colitis | Failed Discontinued | |
AMT-101 (IL-10 oral agonist) +anti-TNFα Details Ulcerative colitis | Failed Discontinued | |
AMT-126 (IL-22) Details GI barrier repair | Failed Discontinued |